In summary, the usage of denosumab and bisphosphonates can cause osteonecrosis, which is now a recognized and clinically relevant disease. It mainly affects people who have received subcutaneous denosumab therapies or intravenous nitrogen-containing bisphosphonates and have underlying malignant diseases. The presence of necrotic bone exposed in the craniofacial region is the clinical characteristic that indicates the presence of the disease. In a large number of cases, it is frequently accompanied by signs of infection, including discomfort, soft tissue edema in the surrounding area, or the development of draining fistulas. Additional complications during the course of the disease could include the involvement of the maxillary sinus or the development of pathological fractures in the jaw.